Gigoux V, Maigret B, Escrieut C, Silvente-Poirot S, Bouisson M, Fehrentz J A, Moroder L, Gully D, Martinez J, Vaysse N, Fourmy A D
INSERUM U151, CHU de Rangueil, Toulouse, France.
Protein Sci. 1999 Nov;8(11):2347-54. doi: 10.1110/ps.8.11.2347.
The knowledge of the binding sites of G protein-coupled cholecystokinin receptors represents important insights that may serve to understand their activation processes and to design or optimize ligands. Our aim was to identify the amino acid of the cholecystokinin-A receptor (CCK-AR) binding site in an interaction with the sulfate of CCK, which is crucial for CCK binding and activity. A three-dimensional model of the [CCK-AR-CCK] complex was built. In this model, Arg197 was the best candidate residue for a ionic interaction with the sulfate of CCK. Arg197 was exchanged for a methionine by site-directed mutagenesis. Wild-type and mutated CCK-AR were transiently expressed in COS-7 cells for pharmacological and functional analysis. The mutated receptor on Arg197 did not bind the agonist radioligand 125I-BH-[Thr, Nle]-CCK-9; however, it bound the nonpeptide antagonist [3H]-SR27,897 as the wild-type receptor. The mutant was approximately 1,470- and 3,200-fold less potent than the wild-type CCK-AR to activate G proteins and to induce inositol phosphate production, respectively. This is consistent with the 500-fold lower potency and 800-fold lower affinity of nonsulfated CCK relative to sulfated CCK on the wild-type receptor. These data, together with those showing that the mutated receptor failed to discriminate nonsulfated and sulfated CCK while it retained other pharmacological features of the CCK-AR, strongly support an interaction between Arg197 of the CCK-AR binding site and the sulfate of CCK. In addition, the mutated CCK-AR resembled the low affinity state of the wild-type CCK-AR, suggesting that Arg197-sulfate interaction regulates conformational changes of the CCK-AR that are required for its physiological activation.
了解G蛋白偶联胆囊收缩素受体的结合位点代表了重要的见解,这可能有助于理解其激活过程以及设计或优化配体。我们的目标是确定胆囊收缩素-A受体(CCK-AR)结合位点中与CCK硫酸盐相互作用的氨基酸,这对CCK的结合和活性至关重要。构建了[CCK-AR-CCK]复合物的三维模型。在该模型中,Arg197是与CCK硫酸盐进行离子相互作用的最佳候选残基。通过定点诱变将Arg197替换为甲硫氨酸。野生型和突变型CCK-AR在COS-7细胞中瞬时表达以进行药理学和功能分析。Arg197处的突变受体不结合激动剂放射性配体125I-BH-[Thr,Nle]-CCK-9;然而,它与野生型受体一样结合非肽拮抗剂[3H]-SR27,897。该突变体激活G蛋白和诱导肌醇磷酸产生的效力分别比野生型CCK-AR低约1470倍和3200倍。这与野生型受体上非硫酸化CCK相对于硫酸化CCK的效力低500倍和亲和力低800倍一致。这些数据,连同那些表明突变受体在保留CCK-AR的其他药理学特征的同时未能区分非硫酸化和硫酸化CCK的数据,有力地支持了CCK-AR结合位点的Arg197与CCK硫酸盐之间的相互作用。此外,突变的CCK-AR类似于野生型CCK-AR的低亲和力状态,表明Arg197-硫酸盐相互作用调节CCK-AR生理激活所需的构象变化。